PMID: 7014986Feb 1, 1981Paper

Serial study of circulating immune complexes before and after renal transplantation

Kidney International
K V JohnyJ B Dossetor

Abstract

To clarify the relationship of circulating immune complexes (CIC) to acute rejection or intercurrent infection, we studied the presence of CIC's by four methods in renal allograft recipients, by serial monitoring, before and after transplantation, of both CIC and donor-specific immunologic parameters. Three of the methods were dependent on the precipitation of CIC with low concentrations of polyethylene glycol (PEG). They were the radioisotopic conglutinin-binding assay, the Clq-binding assay, and the radial immunodiffusion (RID) of IgG and IgM in PEG precipitates. The fourth method was the Raji cell assay. These techniques were applied to sequentially collected serum samples from 26 patients, both before and up to 20 months after transplantation (mean followup, 7.2 months). CIC's were present in 14 out of 26 (54%) patients studied before transplantation. Glomerulonephritis was the primary renal disease in only half of these patients. Of this half, 12 (86%) were positive after transplantation, whereas only 2 of the 12 (17%) with no CIC before transplantation became positive subsequently. CIC's were demonstrable in 19 out of 28 patients (68%) during the posttransplant observation. In five instances (4 patients), they appeared on...Continue Reading

References

May 1, 1979·Transplantation·I MatlJ Kaslík
Apr 1, 1976·Transplantation·T PalosuoF Milgrom
May 10, 1976·The American Journal of Medicine·K D NolphA W Siemsen
May 1, 1977·The American Journal of Medicine·C R Steinman, A Ackad
Aug 1, 1975·The American Journal of Medicine·T H MathewP Kincaid-Smith
Sep 27, 1975·British Medical Journal·G DrivasN Wardle
Mar 1, 1974·The Journal of Experimental Medicine·A N TheofilopoulosF J Dixon
Sep 1, 1965·Immunochemistry·G ManciniJ F Heremans

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.